Back to Search Start Over

Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)

Authors :
Oussama Abla
Sheila Weitzman
Michael Silver
Nancy D. Doolittle
Hervé Ghesquières
Jean-Yves Blay
Tracy T. Batchelor
Kamnesh R. Pradhan
Lauren E. Abrey
Rebecca A. Betensky
Michael F. Guerrera
Joachim M. Baehring
S. Eric Martin
Shafqat Shah
Edward A. Neuwelt
Brian P. O'Neill
The Hospital for sick children [Toronto] (SickKids)
Equipe 11
Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL)
Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
University at Albany [SUNY]
State University of New York (SUNY)
Département Hématologie (FNCLCC)
Centre Léon Bérard [Lyon]
Source :
Clinical Cancer Research, Clinical Cancer Research, American Association for Cancer Research, 2011, 17 (2), pp.346-52. ⟨10.1158/1078-0432.CCR-10-1161⟩
Publication Year :
2011
Publisher :
HAL CCSD, 2011.

Abstract

Purpose: To describe the demographic and clinical features and outcomes for children and adolescents with primary CNS lymphoma (PCNSL). Experimental Design: A retrospective series of children and adolescents with PCNSL was assembled from 10 cancer centers in 3 countries. Results: Twenty-nine patients with a median age of 14 years were identified. Sixteen (55%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or greater. Frontline therapy consisted of chemotherapy only in 20 patients (69%), while 9 (31%) had chemotherapy plus cranial radiotherapy. Most patients received methotrexate (MTX)-based regimens. Overall response rate was 86% (complete remission 69%, partial remission 17%). The 2-year progression-free survival (PFS) and overall survival (OS) rates were 61% and 86%, respectively; the 3-year OS was 82%. Univariate analyses were conducted for age (≤14 vs. >14 years), PS (0 or 1 vs. >1), deep brain lesions, MTX dose, primary treatment with chemotherapy alone, intrathecal chemotherapy, and high-dose therapy. Primary treatment with chemotherapy alone was associated with better overall response rates with an odds ratio (OR) of 0.125 (P = 0.02). There was a marginally significant relationship between higher doses of MTX and response (OR = 1.5, P = 0.06). ECOG-PS of 0 to 1 was the only factor associated with better outcome with hazard ratios of 0.136 (P = 0.017) and 0.073 (P = 0.033) for PFS and OS, respectively. Conclusion: This is the largest series collected of pediatric PCNSL. The outcome of children and adolescents seems to be better than in adults. PS of 0 to 1 is associated with better survival. Clin Cancer Res; 17(2); 346–52. ©2011 AACR.

Details

Language :
English
ISSN :
10780432 and 15573265
Database :
OpenAIRE
Journal :
Clinical Cancer Research, Clinical Cancer Research, American Association for Cancer Research, 2011, 17 (2), pp.346-52. ⟨10.1158/1078-0432.CCR-10-1161⟩
Accession number :
edsair.doi.dedup.....4f8021b2359e4f27d6177221b38879a3
Full Text :
https://doi.org/10.1158/1078-0432.CCR-10-1161⟩